Current Treatment Modalities Associated With Glioblastoma and Its Merits and Demerits

Authors:

Abstract
Glioblastoma multiforme (GBM) is an aggressive primary brain tumor marked by rapid progression, diffuse infiltration, and poor prognosis. Conventional treatments—surgical resection, radiotherapy, and temozolomide chemotherapy—offer limited success due to intratumoral heterogeneity, the blood-brain barrier (BBB), glioma stem-like cells. Novel immunotherapeutic strategies, including immune checkpoint inhibitors, CAR T and CAR-NK cells, dendritic cell vaccines, and oncolytic virotherapy, are under investigation to improve immune-mediated tumor eradication. Tumor-treating fields (TTFs) and targeted molecular therapies show additional promise. This chapter explores the molecular and metabolic landscape of GBM, reviews current and emerging therapies, and underscores the urgent need for integrated, personalized treatment strategies to improve patient outcomes.

This publication has 79 references indexed in Scilit: